NeuroSense Therapeutics (NRSN) Earnings Date & Reports

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

NRSN is expected to report earnings to fall 27.27% to -7 cents per share on March 31

NeuroSense Therapeutics NRSN Stock Earnings Reports

Q4'24

Est.

$-0.08

Q3'24

Beat

by $0.03

Q2'24

Beat

by $0.14

Q1'24

Missed

by $0.14

Q4'23

Beat

by $0.02

The last earnings report on December 18 showed earnings per share of -10 cents, beating the estimate of -14 cents. With 165.52K shares outstanding, the current market capitalization sits at 23.00M.

View a ticker or compare two or three

Compare

NRSN